Share Price and Basic Stock Data
Last Updated: January 10, 2026, 8:46 am
| PEG Ratio | 16.02 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Glenmark Life Sciences Ltd operates in the pharmaceuticals sector, focusing on the production of active pharmaceutical ingredients (APIs). The company’s current market capitalization stands at ₹58,692 Cr, with its stock priced at ₹2,080. Glenmark reported total sales of ₹12,990 Cr for the fiscal year ending March 2023, a notable increase from ₹12,305 Cr in the previous fiscal year. For the trailing twelve months (TTM), sales rose to ₹15,955 Cr, indicating a robust growth trajectory. Quarterly sales figures show a consistent upward trend, with the most recent quarter ending September 2023 recording sales of ₹3,207 Cr. This growth can be attributed to increased demand for pharmaceutical products and a strategic focus on expanding its product portfolio. However, sales dipped in December 2023 to ₹2,507 Cr, highlighting potential volatility in revenue streams. The company’s revenue growth reflects a positive response to market demands, positioning it favorably within the competitive landscape of the Indian pharmaceuticals industry.
Profitability and Efficiency Metrics
Glenmark Life Sciences reported a net profit of ₹1,010 Cr for the fiscal year ending March 2025, following a challenging period marked by fluctuating profits. The operating profit margin (OPM) stood at 39% for the latest reporting period, showcasing the company’s strong cost management and efficient operations. In contrast, OPM dipped to 14% in September 2023, reflecting the impact of rising expenses, which totaled ₹10,712 Cr for the fiscal year 2023. The interest coverage ratio (ICR) was reported at 11.90x, indicating robust ability to meet interest obligations. However, the company faced a significant loss in December 2023, with an operating profit of -₹209 Cr, underscoring periods of financial strain. The return on equity (ROE) stood at 15.8%, while return on capital employed (ROCE) was reported at 19.4%, both of which are competitive within the sector and reflect effective capital utilization. These profitability metrics suggest that Glenmark is positioned well against sector averages, although recent fluctuations highlight the need for vigilance.
Balance Sheet Strength and Financial Ratios
Glenmark Life Sciences maintains a solid balance sheet, with total assets reported at ₹15,991 Cr and total liabilities at ₹14,358 Cr as of March 2025. The company’s reserves amount to ₹9,554 Cr, providing a strong buffer against financial uncertainties. Borrowings stood at ₹1,224 Cr, indicating a low debt level relative to equity, with a total debt-to-equity ratio of 0.24x. This conservative borrowing strategy enhances financial stability and lowers risk exposure. The quick ratio of 1.05 and current ratio of 1.56 further affirm the company’s liquidity position, allowing it to meet short-term obligations comfortably. The price-to-book value (P/BV) ratio was recorded at 4.91x, reflecting market confidence in the company’s growth prospects. However, the enterprise value (EV) to EBITDA ratio stood at 17.83x, which may indicate that the stock is relatively overvalued compared to earnings. Overall, Glenmark’s financial ratios suggest a robust financial foundation, although the elevated valuation metrics warrant careful consideration from investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Glenmark Life Sciences indicates a diversified investor base, with promoters holding 46.64% of the shares. Foreign institutional investors (FIIs) account for 20.73%, while domestic institutional investors (DIIs) hold 18.61%. Public shareholding stands at 13.97%, reflecting a steady interest from retail investors. The number of shareholders decreased from 3,00,106 in December 2022 to 1,98,789 by September 2025, indicating a trend towards consolidation among larger investors. The consistent promoter holding suggests a strong alignment of interests between management and shareholders, which is typically seen as a positive indicator for long-term stability. However, the decline in the number of shareholders may raise concerns about liquidity and market participation. With FIIs showing a slight decrease from 23.19% in December 2022 to 20.73%, it is essential to monitor investor sentiment closely, as changes in institutional ownership can impact stock performance significantly.
Outlook, Risks, and Final Insight
Glenmark Life Sciences is poised for potential growth, bolstered by its solid financial metrics and a growing demand for pharmaceuticals. However, the company faces risks, including fluctuating operational profitability and market volatility, as evidenced by the loss reported in December 2023. Additionally, increasing competition in the pharmaceutical sector could pressure margins. The company’s ability to maintain its operating profit margin while managing costs will be crucial for sustaining profitability. On the upside, Glenmark’s strategic investments in expanding its API portfolio and potential new product launches could drive revenue growth. Investors should remain cautious, balancing the positive outlook against the inherent risks of market fluctuations and operational challenges. The company’s financial health, characterized by low debt and strong reserves, positions it favorably for navigating these challenges effectively. Overall, Glenmark Life Sciences presents a compelling investment opportunity, albeit with the need for vigilant monitoring of its operational performance and market conditions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 208/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,259 Cr. | 391 | 479/192 | 88.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.8 Cr. | 45.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.9 Cr. | 39.5 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,294.49 Cr | 1,133.13 | 52.77 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,018 | 3,100 | 3,001 | 3,036 | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 |
| Expenses | 2,539 | 2,626 | 2,603 | 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 |
| Operating Profit | 479 | 474 | 398 | 437 | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 |
| OPM % | 16% | 15% | 13% | 14% | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% | 39% |
| Other Income | 86 | 209 | -696 | -32 | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1,184 |
| Interest | 83 | 97 | 109 | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 |
| Depreciation | 146 | 152 | 135 | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 |
| Profit before tax | 337 | 435 | -542 | 151 | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 |
| Tax % | 17% | 33% | -26% | -14% | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% | 37% |
| Net Profit | 279 | 291 | -403 | 173 | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 | 610 |
| EPS in Rs | 9.23 | 9.66 | -15.18 | 5.31 | -2.90 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 |
Last Updated: December 26, 2025, 6:46 pm
Below is a detailed analysis of the quarterly data for Glenmark Life Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 6,047.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,264.00 Cr. (Jun 2025) to 6,047.00 Cr., marking an increase of 2,783.00 Cr..
- For Expenses, as of Sep 2025, the value is 3,687.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,684.00 Cr. (Jun 2025) to 3,687.00 Cr., marking an increase of 1,003.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 2,360.00 Cr.. The value appears strong and on an upward trend. It has increased from 581.00 Cr. (Jun 2025) to 2,360.00 Cr., marking an increase of 1,779.00 Cr..
- For OPM %, as of Sep 2025, the value is 39.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Jun 2025) to 39.00%, marking an increase of 21.00%.
- For Other Income, as of Sep 2025, the value is -1,184.00 Cr.. The value appears to be declining and may need further review. It has decreased from -297.00 Cr. (Jun 2025) to -1,184.00 Cr., marking a decrease of 887.00 Cr..
- For Interest, as of Sep 2025, the value is 66.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 58.00 Cr. (Jun 2025) to 66.00 Cr., marking an increase of 8.00 Cr..
- For Depreciation, as of Sep 2025, the value is 141.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 130.00 Cr. (Jun 2025) to 141.00 Cr., marking an increase of 11.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 967.00 Cr.. The value appears strong and on an upward trend. It has increased from 96.00 Cr. (Jun 2025) to 967.00 Cr., marking an increase of 871.00 Cr..
- For Tax %, as of Sep 2025, the value is 37.00%. The value appears to be improving (decreasing) as expected. It has decreased from 51.00% (Jun 2025) to 37.00%, marking a decrease of 14.00%.
- For Net Profit, as of Sep 2025, the value is 610.00 Cr.. The value appears strong and on an upward trend. It has increased from 47.00 Cr. (Jun 2025) to 610.00 Cr., marking an increase of 563.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 21.63. The value appears strong and on an upward trend. It has increased from 1.66 (Jun 2025) to 21.63, marking an increase of 19.97.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:39 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,005 | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 12,990 | 11,813 | 13,322 | 15,955 |
| Expenses | 4,914 | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 10,712 | 10,618 | 10,970 | 11,854 |
| Operating Profit | 1,091 | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 2,278 | 1,195 | 2,351 | 4,101 |
| OPM % | 18% | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 18% | 10% | 18% | 26% |
| Other Income | 11 | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -449 | 336 | -259 | -1,811 |
| Interest | 189 | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 350 | 516 | 207 | 244 |
| Depreciation | 217 | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 611 | 582 | 486 | 519 |
| Profit before tax | 697 | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 868 | 434 | 1,399 | 1,527 |
| Tax % | 22% | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 57% | 430% | 25% | |
| Net Profit | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,010 |
| EPS in Rs | 19.99 | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 35.78 |
| Dividend Payout % | 0% | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.72% | 255.50% | 49.26% | -27.50% | 15.05% | -16.11% | 25.00% | 2.47% | -62.07% | -480.37% | 173.01% |
| Change in YoY Net Profit Growth (%) | 0.00% | 317.22% | -206.24% | -76.76% | 42.55% | -31.16% | 41.11% | -22.53% | -64.55% | -418.30% | 653.38% |
Glenmark Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 5% |
| 3 Years: | 3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 12% |
| 3 Years: | 6% |
| TTM: | 159% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 33% |
| 3 Years: | 74% |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | -1% |
| 3 Years: | -10% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:57 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 2,956 | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,821 | 9,554 |
| Borrowings | 3,267 | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,627 | 1,231 | 2,473 | 1,224 |
| Other Liabilities | 2,176 | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,228 | 5,279 | 4,669 | 8,196 |
| Total Liabilities | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,329 | 14,358 | 15,991 | 19,002 |
| Fixed Assets | 3,091 | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 6,202 | 4,210 | 4,487 | 5,210 |
| CWIP | 5 | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,251 | 662 | 835 | 695 |
| Investments | 0 | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 |
| Other Assets | 5,331 | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 11,830 | 8,697 | 10,613 | 13,054 |
| Total Assets | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,329 | 14,358 | 15,991 | 19,002 |
Below is a detailed analysis of the balance sheet data for Glenmark Life Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 28.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 28.00 Cr..
- For Reserves, as of Sep 2025, the value is 9,554.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,821.00 Cr. (Mar 2025) to 9,554.00 Cr., marking an increase of 733.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,224.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,473.00 Cr. (Mar 2025) to 1,224.00 Cr., marking a decrease of 1,249.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 8,196.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,669.00 Cr. (Mar 2025) to 8,196.00 Cr., marking an increase of 3,527.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 19,002.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15,991.00 Cr. (Mar 2025) to 19,002.00 Cr., marking an increase of 3,011.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 5,210.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,487.00 Cr. (Mar 2025) to 5,210.00 Cr., marking an increase of 723.00 Cr..
- For CWIP, as of Sep 2025, the value is 695.00 Cr.. The value appears to be declining and may need further review. It has decreased from 835.00 Cr. (Mar 2025) to 695.00 Cr., marking a decrease of 140.00 Cr..
- For Investments, as of Sep 2025, the value is 42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 56.00 Cr. (Mar 2025) to 42.00 Cr., marking a decrease of 14.00 Cr..
- For Other Assets, as of Sep 2025, the value is 13,054.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,613.00 Cr. (Mar 2025) to 13,054.00 Cr., marking an increase of 2,441.00 Cr..
- For Total Assets, as of Sep 2025, the value is 19,002.00 Cr.. The value appears strong and on an upward trend. It has increased from 15,991.00 Cr. (Mar 2025) to 19,002.00 Cr., marking an increase of 3,011.00 Cr..
Notably, the Reserves (9,554.00 Cr.) exceed the Borrowings (1,224.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -2.00 | -2.00 | -2.00 | -3.00 | -3.00 | -3.00 | -2.00 | -1.00 | -2.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 131 | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 | 92 |
| Inventory Days | 191 | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 | 254 |
| Days Payable | 279 | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 | 216 |
| Cash Conversion Cycle | 43 | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 | 129 |
| Working Capital Days | 62 | 47 | 51 | 125 | 99 | 64 | 54 | 67 | 65 | 141 | -2 | 44 |
| ROCE % | 15% | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% | 10% | 12% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 12,636,078 | 2.67 | 2459.23 | N/A | N/A | N/A |
| Invesco India Midcap Fund | 1,864,031 | 3.63 | 362.78 | N/A | N/A | N/A |
| Invesco India Contra Fund | 1,850,088 | 1.75 | 360.06 | 1,662,235 | 2025-12-15 01:33:05 | 11.3% |
| Invesco India Large & Mid Cap Fund | 1,342,939 | 2.78 | 261.36 | 1,205,107 | 2025-11-03 01:08:21 | 11.44% |
| HDFC Large and Mid Cap Fund | 1,048,046 | 0.71 | 203.97 | N/A | N/A | N/A |
| Mahindra Manulife Multi Cap Fund | 989,000 | 3.14 | 192.48 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 952,877 | 1.02 | 185.45 | N/A | N/A | N/A |
| Mirae Asset Healthcare Fund | 941,043 | 6.51 | 183.15 | 956,043 | 2025-12-15 01:33:05 | -1.57% |
| HDFC Balanced Advantage Fund | 885,046 | 0.16 | 172.25 | N/A | N/A | N/A |
| Tata Arbitrage Fund | 859,500 | 0.83 | 167.28 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Diluted EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Cash EPS (Rs.) | 54.33 | -30.18 | 35.04 | 52.46 | 50.10 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Revenue From Operations / Share (Rs.) | 472.08 | 418.62 | 460.36 | 436.08 | 387.85 |
| PBDIT / Share (Rs.) | 87.36 | 72.13 | 91.97 | 88.14 | 75.65 |
| PBIT / Share (Rs.) | 70.13 | 51.50 | 70.31 | 70.89 | 59.93 |
| PBT / Share (Rs.) | 49.58 | 1.29 | 30.78 | 51.08 | 48.99 |
| Net Profit / Share (Rs.) | 37.11 | -50.80 | 13.37 | 35.21 | 34.38 |
| NP After MI And SOA / Share (Rs.) | 37.11 | -53.21 | 10.53 | 33.37 | 34.38 |
| PBDIT Margin (%) | 18.50 | 17.22 | 19.97 | 20.21 | 19.50 |
| PBIT Margin (%) | 14.85 | 12.30 | 15.27 | 16.25 | 15.45 |
| PBT Margin (%) | 10.50 | 0.30 | 6.68 | 11.71 | 12.63 |
| Net Profit Margin (%) | 7.86 | -12.13 | 2.90 | 8.07 | 8.86 |
| NP After MI And SOA Margin (%) | 7.86 | -12.71 | 2.28 | 7.65 | 8.86 |
| Return on Networth / Equity (%) | 11.83 | -19.13 | 3.13 | 10.36 | 13.73 |
| Return on Capital Employeed (%) | 19.62 | 17.01 | 13.84 | 16.13 | 14.83 |
| Return On Assets (%) | 6.52 | -10.45 | 1.53 | 5.51 | 6.21 |
| Long Term Debt / Equity (X) | 0.05 | 0.00 | 0.40 | 0.28 | 0.55 |
| Total Debt / Equity (X) | 0.24 | 0.12 | 0.45 | 0.40 | 0.66 |
| Asset Turnover Ratio (%) | 0.87 | 0.70 | 0.71 | 0.42 | 0.42 |
| Current Ratio (X) | 1.56 | 1.28 | 1.96 | 1.77 | 1.75 |
| Quick Ratio (X) | 1.05 | 0.84 | 1.37 | 1.23 | 1.21 |
| Inventory Turnover Ratio (X) | 4.81 | 1.15 | 1.31 | 1.85 | 1.85 |
| Dividend Payout Ratio (NP) (%) | 6.73 | -4.69 | 23.73 | 7.49 | 7.27 |
| Dividend Payout Ratio (CP) (%) | 4.60 | -7.66 | 7.76 | 4.93 | 4.99 |
| Earning Retention Ratio (%) | 93.27 | 104.69 | 76.27 | 92.51 | 92.73 |
| Cash Earning Retention Ratio (%) | 95.40 | 107.66 | 92.24 | 95.07 | 95.01 |
| Interest Coverage Ratio (X) | 11.90 | 3.94 | 7.42 | 8.34 | 6.04 |
| Interest Coverage Ratio (Post Tax) (X) | 7.86 | -0.80 | 4.27 | 5.21 | 3.62 |
| Enterprise Value (Cr.) | 43947.27 | 26350.45 | 16364.27 | 15087.86 | 16656.12 |
| EV / Net Operating Revenue (X) | 3.30 | 2.23 | 1.26 | 1.23 | 1.52 |
| EV / EBITDA (X) | 17.83 | 12.95 | 6.31 | 6.07 | 7.80 |
| MarketCap / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| Retention Ratios (%) | 93.26 | 104.69 | 76.26 | 92.50 | 92.72 |
| Price / BV (X) | 4.91 | 3.44 | 1.38 | 1.37 | 1.86 |
| Price / Net Operating Revenue (X) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
| EarningsYield | 0.02 | -0.05 | 0.02 | 0.07 | 0.07 |
After reviewing the key financial ratios for Glenmark Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.22 (Mar 24) to 37.11, marking an increase of 90.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 54.33. This value is within the healthy range. It has increased from -30.18 (Mar 24) to 54.33, marking an increase of 84.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.60. It has increased from 278.09 (Mar 24) to 313.60, marking an increase of 35.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 472.08. It has increased from 418.62 (Mar 24) to 472.08, marking an increase of 53.46.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 87.36. This value is within the healthy range. It has increased from 72.13 (Mar 24) to 87.36, marking an increase of 15.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 70.13. This value is within the healthy range. It has increased from 51.50 (Mar 24) to 70.13, marking an increase of 18.63.
- For PBT / Share (Rs.), as of Mar 25, the value is 49.58. This value is within the healthy range. It has increased from 1.29 (Mar 24) to 49.58, marking an increase of 48.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -50.80 (Mar 24) to 37.11, marking an increase of 87.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 37.11. This value is within the healthy range. It has increased from -53.21 (Mar 24) to 37.11, marking an increase of 90.32.
- For PBDIT Margin (%), as of Mar 25, the value is 18.50. This value is within the healthy range. It has increased from 17.22 (Mar 24) to 18.50, marking an increase of 1.28.
- For PBIT Margin (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 14.85, marking an increase of 2.55.
- For PBT Margin (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 10.50, marking an increase of 10.20.
- For Net Profit Margin (%), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -12.13 (Mar 24) to 7.86, marking an increase of 19.99.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 8. It has increased from -12.71 (Mar 24) to 7.86, marking an increase of 20.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.83. This value is below the healthy minimum of 15. It has increased from -19.13 (Mar 24) to 11.83, marking an increase of 30.96.
- For Return on Capital Employeed (%), as of Mar 25, the value is 19.62. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 19.62, marking an increase of 2.61.
- For Return On Assets (%), as of Mar 25, the value is 6.52. This value is within the healthy range. It has increased from -10.45 (Mar 24) to 6.52, marking an increase of 16.97.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.12 (Mar 24) to 0.24, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has increased from 0.70 (Mar 24) to 0.87, marking an increase of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has increased from 1.28 (Mar 24) to 1.56, marking an increase of 0.28.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has increased from 0.84 (Mar 24) to 1.05, marking an increase of 0.21.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.81. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 4.81, marking an increase of 3.66.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.73. This value is below the healthy minimum of 20. It has increased from -4.69 (Mar 24) to 6.73, marking an increase of 11.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.60. This value is below the healthy minimum of 20. It has increased from -7.66 (Mar 24) to 4.60, marking an increase of 12.26.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.27. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.27, marking a decrease of 11.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.40. This value exceeds the healthy maximum of 70. It has decreased from 107.66 (Mar 24) to 95.40, marking a decrease of 12.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.90. This value is within the healthy range. It has increased from 3.94 (Mar 24) to 11.90, marking an increase of 7.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.86. This value is within the healthy range. It has increased from -0.80 (Mar 24) to 7.86, marking an increase of 8.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 43,947.27. It has increased from 26,350.45 (Mar 24) to 43,947.27, marking an increase of 17,596.82.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.30. This value exceeds the healthy maximum of 3. It has increased from 2.23 (Mar 24) to 3.30, marking an increase of 1.07.
- For EV / EBITDA (X), as of Mar 25, the value is 17.83. This value exceeds the healthy maximum of 15. It has increased from 12.95 (Mar 24) to 17.83, marking an increase of 4.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For Retention Ratios (%), as of Mar 25, the value is 93.26. This value exceeds the healthy maximum of 70. It has decreased from 104.69 (Mar 24) to 93.26, marking a decrease of 11.43.
- For Price / BV (X), as of Mar 25, the value is 4.91. This value exceeds the healthy maximum of 3. It has increased from 3.44 (Mar 24) to 4.91, marking an increase of 1.47.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.29 (Mar 24) to 3.26, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.02, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glenmark Life Sciences Ltd:
- Net Profit Margin: 7.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 19.62% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.83% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 22.5 (Industry average Stock P/E: 52.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B/2, Mahalaxmi Chambers, Mumbai Maharashtra 400026 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Glenn Saldanha | Chairman & Managing Director |
| Mrs. Cherylann Pinto | Executive Director |
| Mr. Anurag Mantri | Executive Director & Global CFO |
| Mrs. B E Saldanha | Non Executive Director |
| Ms. Saira Ramasastry | Ind. Non-Executive Director |
| Mrs. Vijayalakshmi Iyer | Ind. Non-Executive Director |
| Mr. Pradeep Kumar Sinha | Ind. Non-Executive Director |
| Mr. Dipankar Bhattacharjee | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Glenmark Life Sciences Ltd?
Glenmark Life Sciences Ltd's intrinsic value (as of 11 January 2026) is ₹968.12 which is 51.76% lower the current market price of ₹2,007.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹56,643 Cr. market cap, FY2025-2026 high/low of ₹2,286/1,275, reserves of ₹9,554 Cr, and liabilities of ₹19,002 Cr.
What is the Market Cap of Glenmark Life Sciences Ltd?
The Market Cap of Glenmark Life Sciences Ltd is 56,643 Cr..
What is the current Stock Price of Glenmark Life Sciences Ltd as on 11 January 2026?
The current stock price of Glenmark Life Sciences Ltd as on 11 January 2026 is ₹2,007.
What is the High / Low of Glenmark Life Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Glenmark Life Sciences Ltd stocks is ₹2,286/1,275.
What is the Stock P/E of Glenmark Life Sciences Ltd?
The Stock P/E of Glenmark Life Sciences Ltd is 22.5.
What is the Book Value of Glenmark Life Sciences Ltd?
The Book Value of Glenmark Life Sciences Ltd is 340.
What is the Dividend Yield of Glenmark Life Sciences Ltd?
The Dividend Yield of Glenmark Life Sciences Ltd is 0.12 %.
What is the ROCE of Glenmark Life Sciences Ltd?
The ROCE of Glenmark Life Sciences Ltd is 19.4 %.
What is the ROE of Glenmark Life Sciences Ltd?
The ROE of Glenmark Life Sciences Ltd is 15.8 %.
What is the Face Value of Glenmark Life Sciences Ltd?
The Face Value of Glenmark Life Sciences Ltd is 1.00.